Abstract
Plasma amyloid β protein (Aβ42) levels and late onset Alzheimer's disease (LOAD) have been linked to the same region on chromosome 10q. The PLAU gene within this region encodes urokinase-type plasminogen activator, which converts plasminogen to plasmin. Aβ aggregates induce PLAU expression thereby increasing plasmin, which degrades both aggregated and non-aggregated forms of Aβ. We evaluated single nucleotide polymorphisms (SNPs) in PLAU for association with Aβ42 and LOAD. PLAU SNP compound genotypes composed of haplotype pairs showed significant association with AD in three independent case-control series. PLAU SNP haplotypes associated significantly with plasma Aβ42 in 10 extended LOAD families. One of the SNPs analyzed was a missense C/T polymorphism in exon 6 of PLAU (PLAU_1 = rs2227564), which causes a proline to leucine change (P141L). We analyzed PLAU_1 for association with AD in six case-control series and 24 extended LOAD families. The CT and TT PLAU_1 genotypes showed association (P = 0.05) with an overall estimated odds ratio of 1.2 (1.0-1.5). The CT and TT genotypes of PLAU_1 were also associated with significant age-dependent elevation of plasma Aβ42 in 24 extended LOAD families (P = 0.0006). In knockout mice lacking the PLAU gene, plasma - but not brain - Aβ42 as well as Aβ40 was significantly elevated, also in an age-dependent manner. The PLAU_1 associations were independent of the associations we found among plasma Aβ42, LOAD and variants in the IDE or VR22 region. These results provide strong evidence that PLAU or a nearby gene is involved in the development of LOAD. PLAU_1 is a plausible pathogenic mutation that could act by increasing Aβ42, but additional biological experiments are required to show this definitively.
| Original language | English |
|---|---|
| Pages (from-to) | 447-460 |
| Number of pages | 14 |
| Journal | Human Molecular Genetics |
| Volume | 14 |
| Issue number | 3 |
| DOIs | |
| State | Published - Feb 1 2005 |
Bibliographical note
Funding Information:We acknowledge the Mayo Clinic and UKy ADRC members for their help in the collection of samples. We are grateful to all of the individuals who participated in this study, without whom this work would not be possible. This study was supported by the NIH grants AG18023 (S.G.Y.), AG06656 (S.G.Y.), AG20903 (N.E.T.), AG21545 (S.E.), 2P50AG05144 (W.M.), a grant from American Federation for Aging Research Grant PD01062 (N.E.T.) and a Robert and Clarice Smith Fellowship (N.E.T.).
Funding
We acknowledge the Mayo Clinic and UKy ADRC members for their help in the collection of samples. We are grateful to all of the individuals who participated in this study, without whom this work would not be possible. This study was supported by the NIH grants AG18023 (S.G.Y.), AG06656 (S.G.Y.), AG20903 (N.E.T.), AG21545 (S.E.), 2P50AG05144 (W.M.), a grant from American Federation for Aging Research Grant PD01062 (N.E.T.) and a Robert and Clarice Smith Fellowship (N.E.T.).
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | AG06656, AG21545, AG20903, AG18023 |
| National Institutes of Health (NIH) | |
| National Institute on Aging | P50AG005144 |
| National Institute on Aging | |
| American Federation for Aging Research | PD01062 |
| American Federation for Aging Research |
ASJC Scopus subject areas
- Molecular Biology
- Genetics
- Genetics(clinical)